BiotechTube

TP-03 + TP-03 Vehicle

Phase 2Completed
0 watching 0 views this week⚡ Active
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Meibomian Gland Dysfunction

Conditions

Meibomian Gland Dysfunction, Blepharitis, Demodex Infestation

Trial Timeline

Aug 3, 2022 → May 18, 2023

NCT ID
NCT05454956

About TP-03 + TP-03 Vehicle

TP-03 + TP-03 Vehicle is a phase 2 stage product being developed by Tarsus Pharmaceuticals for Meibomian Gland Dysfunction. The current trial status is completed. This product is registered under clinical trial identifier NCT05454956. Target conditions include Meibomian Gland Dysfunction, Blepharitis, Demodex Infestation.

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT05454956Phase 2Completed
NCT04784091Phase 3Completed

Competing Products

3 competing products in Meibomian Gland Dysfunction

See all competitors
ProductCompanyStageHype Score
Vehicle of TP-03Tarsus PharmaceuticalsPhase 2
47
SHR8058 eye drops + saline eye drops.Jiangsu Hengrui MedicinePhase 3
77
AzasiteMerckPhase 2
52

Other Products from Tarsus Pharmaceuticals

Lotilaner ophthalmic solution, 0.25% + Vehicle controlApproved
80
TP-03 + TP-03 VehiclePhase 3
72
TP-03, 0.25% + TP-03 VehiclePhase 2/3
60
Vehicle of TP-03Phase 2
47
Lotilaner Gel, 2.0%Phase 2
47